<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36899872</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>24</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">736</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12050736</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary muscles and eventual respiratory failure. Non-motor symptoms, such as cognitive and behavioral changes, frequently occur over the course of the disease. Considering its poor prognosis with a median survival time of 2 to 4 years and limited causal treatment options, an early diagnosis of ALS plays an essential role. In the past, diagnosis has primarily been determined by clinical findings supported by electrophysiological and laboratory measurements. To increase diagnostic accuracy, reduce diagnostic delay, optimize stratification in clinical trials and provide quantitative monitoring of disease progression and treatment responsivity, research on disease-specific and feasible fluid biomarkers, such as neurofilaments, has been intensely pursued. Advances in imaging techniques have additionally yielded diagnostic benefits. Growing perception and greater availability of genetic testing facilitate early identification of pathogenic ALS-related gene mutations, predictive testing and access to novel therapeutic agents in clinical trials addressing disease-modified therapies before the advent of the first clinical symptoms. Lately, personalized survival prediction models have been proposed to offer a more detailed disclosure of the prognosis for the patient. In this review, the established procedures and future directions in the diagnostics of ALS are summarized to serve as a practical guideline and to improve the diagnostic pathway of this burdensome disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vidovic</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1453-1681</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;schen</LastName><ForeName>Lars Hendrik</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-2805-3270</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brakemeier</LastName><ForeName>Svenja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Translational Neuro and Behavioral Sciences (C-TNBS), University Hospital Essen, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machetanz</LastName><ForeName>Gerrit</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8955-5306</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center, University of Rostock, 18147 Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-Gomez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1581-474X</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology II, University Hospital Bonn, 53115 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroimmunology, Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">MND</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">diagnostics</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList><CoiStatement>L.H.M. reports personal fees from Biohaven Pharmaceuticals and a speaker honorarium from Forum f&#xfc;r Medizinische Fortbildung, both outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36899872</ArticleId><ArticleId IdType="pmc">PMC10000757</ArticleId><ArticleId IdType="doi">10.3390/cells12050736</ArticleId><ArticleId IdType="pii">cells12050736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Recent Advances in the Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. Lancet Neurol. 2022;21:480&#x2013;493. doi: 10.1016/S1474-4422(21)00465-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman E.L., Goutman S.A., Petri S., Mazzini L., Savelieff M.G., Shaw P.J., Sobue G. Amyotrophic Lateral Sclerosis. Lancet. 2022;400:1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;t&#x11b;tk&#xe1;&#x159;ov&#xe1; I., Ehler E. Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date. Diagnostics. 2021;11:231. doi: 10.3390/diagnostics11020231.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11020231</ArticleId><ArticleId IdType="pmc">PMC7913557</ArticleId><ArticleId IdType="pubmed">33546386</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D., Morren J.A., Pioro E.P. Time to Diagnosis and Factors Affecting Diagnostic Delay in Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2020;417:117054. doi: 10.1016/j.jns.2020.117054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Weise D., Menze I., Metelmann M.C.F., Woost T.B., Classen J., Otto Pelz J. Multimodal Assessment of Autonomic Dysfunction in Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2022;29:715&#x2013;723. doi: 10.1111/ene.15177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15177</ArticleId><ArticleId IdType="pubmed">34748270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R., Hicks S., Berna C.M., Kennard C., Talbot K., Turner M.R. Oculomotor Dysfunction in Amyotrophic Lateral Sclerosis: A Comprehensive Review. Arch. Neurol. 2011;68:857&#x2013;861. doi: 10.1001/archneurol.2011.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.130</ArticleId><ArticleId IdType="pubmed">21747027</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R., Verstraete E., van den Heuvel M.P., Veldink J.H., van den Berg L.H. Patterns of Symptom Development in Patients with Motor Neuron Disease. Amyotroph. Lateral Scler. Front. Degener. 2018;19:21&#x2013;28. doi: 10.1080/21678421.2017.1386688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1386688</ArticleId><ArticleId IdType="pubmed">29037065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy D., Severson K., Ghosh S., Sachs K., Glass J.D., Fournier C.N., Herrington T.M., Berry J.D., Ng K., Fraenkel E. Identifying Patterns in Amyotrophic Lateral Sclerosis Progression from Sparse Longitudinal Data. Nat. Comput. Sci. 2022;2:605&#x2013;616. doi: 10.1038/s43588-022-00299-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43588-022-00299-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 1994;124:96&#x2013;107. doi: 10.1016/0022-510X(94)90191-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O., Kiernan M.C., Chi&#xf2; A., Rix-Brooks B., van den Berg L.H. Amyotrophic Lateral Sclerosis: Moving towards a New Classification System. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E., Fang F. Epidemiology of Amyotrophic Lateral Sclerosis: An Update of Recent Literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilbourn A.J. The &#x201c;Split Hand Syndrome&#x201d;. Muscle Nerve. 2000;23:138. doi: 10.1002/(SICI)1097-4598(200001)23:1&lt;138::AID-MUS22&gt;3.0.CO;2-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(200001)23:1&lt;138::AID-MUS22&gt;3.0.CO;2-7</ArticleId><ArticleId IdType="pubmed">10590421</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Wicks P., Brownstein C.A., Massagli M.P., Toronjo M., Talbot K., Al-Chalabi A. Concordance between Site of Onset and Limb Dominance in Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2011;82:853&#x2013;854. doi: 10.1136/jnnp.2010.208413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.208413</ArticleId><ArticleId IdType="pubmed">20562391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F., Jin J., Chen Q., Kang L., Jia R., Qin X., Liu X., Dang Y., Dang J. Dissociated Lower Limb Muscle Involvement in Amyotrophic Lateral Sclerosis and Its Differential Diagnosis Value. Sci. Rep. 2019;9:17786. doi: 10.1038/s41598-019-54372-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-54372-y</ArticleId><ArticleId IdType="pmc">PMC6883028</ArticleId><ArticleId IdType="pubmed">31780761</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M. Why Are Upper Motor Neuron Signs Difficult to Elicit in Amyotrophic Lateral Sclerosis? J. Neurol. Neurosurg. Psychiatry. 2012;83:659&#x2013;662. doi: 10.1136/jnnp-2012-302315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302315</ArticleId><ArticleId IdType="pubmed">22496581</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W., Simon N.G., Grosskreutz J., Turner M.R., Vucic S., Kiernan M.C. Assessment of the Upper Motor Neuron in Amyotrophic Lateral Sclerosis. Clin. Neurophysiol. 2016;127:2643&#x2013;2660. doi: 10.1016/j.clinph.2016.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2016.04.025</ArticleId><ArticleId IdType="pubmed">27291884</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic Lateral Sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidovic M., Aust E., Hermann A., G&#xfc;nther R. The Palmomental Reflex in Amyotrophic Lateral Sclerosis&#x2014;A Clinical Sign of Executive or Motor Dysfunction? Amyotroph. Lateral Scler. Front. Degener. 2021;22:588&#x2013;591. doi: 10.1080/21678421.2021.1883667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1883667</ArticleId><ArticleId IdType="pubmed">33655811</ArticleId></ArticleIdList></Reference><Reference><Citation>Liewluck T., Saperstein D.S. Progressive Muscular Atrophy. Neurol. Clin. 2015;33:761&#x2013;773. doi: 10.1016/j.ncl.2015.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.005</ArticleId><ArticleId IdType="pubmed">26515620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W.-K., Liu X., Sandner J., Pasmantier M., Andrews J., Rowland L.P., Mitsumoto H. Study of 962 Patients Indicates Progressive Muscular Atrophy Is a Form of ALS. Neurology. 2009;73:1686&#x2013;1692. doi: 10.1212/WNL.0b013e3181c1dea3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1dea3</ArticleId><ArticleId IdType="pmc">PMC2788803</ArticleId><ArticleId IdType="pubmed">19917992</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Barohn R.J., Corcia P., Fink J.K., Harms M.B., Kiernan M.C., Ravits J., Silani V., Simmons Z., Statland J., et al. Primary Lateral Sclerosis: Consensus Diagnostic Criteria. J. Neurol. Neurosurg. Psychiatry. 2020;91:373&#x2013;377. doi: 10.1136/jnnp-2019-322541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId><ArticleId IdType="pmc">PMC7147236</ArticleId><ArticleId IdType="pubmed">32029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Moglia C., Mazzini L., Mora G., PARALS study group Phenotypic Heterogeneity of Amyotrophic Lateral Sclerosis: A Population Based Study. J. Neurol. Neurosurg. Psychiatry. 2011;82:740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera L.C., Mathers S., Talman P., Galtrey C., Parkinson M.H., Ganesalingam J., Willey E., Ampong M.A., Ellis C.M., Shaw C.E., et al. Natural History and Clinical Features of the Flail Arm and Flail Leg ALS Variants. Neurology. 2009;72:1087&#x2013;1094. doi: 10.1212/01.wnl.0000345041.83406.a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000345041.83406.a2</ArticleId><ArticleId IdType="pmc">PMC2821838</ArticleId><ArticleId IdType="pubmed">19307543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M.T., Ellis C.M., Al-Chalabi A., Leigh P.N., Shaw C.E. Flail Arm Syndrome: A Distinctive Variant of Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 1998;65:950&#x2013;951. doi: 10.1136/jnnp.65.6.950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.65.6.950</ArticleId><ArticleId IdType="pmc">PMC2170397</ArticleId><ArticleId IdType="pubmed">9854987</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic Lateral Sclerosis: A Clinical Review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M., Pinto S., Swash M. Association of Paraspinal and Diaphragm Denervation in ALS. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis. 2010;11:63&#x2013;66. doi: 10.3109/17482960902730080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902730080</ArticleId><ArticleId IdType="pubmed">19533450</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The Phenotypic Variability of Amyotrophic Lateral Sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen B. Diagnostic Criteria for Amyotrophic Lateral Sclerosis from El Escorial to Gold Coast. Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 2020;131:1962&#x2013;1963. doi: 10.1016/j.clinph.2020.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.012</ArticleId><ArticleId IdType="pubmed">32418823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee R., O&#x2019;Gorman C.M. Teaching Video NeuroImages: The Pathologic Deep Abdominal Reflex. Neurology. 2017;89:e245. doi: 10.1212/WNL.0000000000004651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004651</ArticleId><ArticleId IdType="pubmed">29133615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabally Y.A., Hbahbih M., Abbott R.J. Hemiplegic ALS: Mills Syndrome. Neurology. 2005;64:1984&#x2013;1985. doi: 10.1212/01.WNL.0000163995.62871.A4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000163995.62871.A4</ArticleId><ArticleId IdType="pubmed">15955966</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiser S.R., Mitra D., Williams T.L., Baker M.R. Mills&#x2019; Syndrome Revisited. J. Neurol. 2019;266:667&#x2013;679. doi: 10.1007/s00415-019-09186-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09186-3</ArticleId><ArticleId IdType="pmc">PMC6394692</ArticleId><ArticleId IdType="pubmed">30631918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastaut J.L., Bartolomei F. Mills&#x2019; Syndrome: Ascending (or Descending) Progressive Hemiplegia: A Hemiplegic Form of Primary Lateral Sclerosis? J. Neurol. Neurosurg. Psychiatry. 1994;57:1280&#x2013;1281. doi: 10.1136/jnnp.57.10.1280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.10.1280</ArticleId><ArticleId IdType="pmc">PMC485513</ArticleId><ArticleId IdType="pubmed">7931406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutter-Locher Z., Turner M.R., Leigh P.N., Al-Chalabi A. Analysis of Terms Used for the Diagnosis and Classification of Amyotrophic Lateral Sclerosis and Motor Neuron Disease. Amyotroph. Lateral Scler. Front. Degener. 2016;17:600&#x2013;604. doi: 10.1080/21678421.2016.1181766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1181766</ArticleId><ArticleId IdType="pubmed">27188215</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M., Dengler R., Eisen A., England J.D., Kaji R., Kimura J., Mills K., Mitsumoto H., Nodera H., Shefner J., et al. Electrodiagnostic Criteria for Diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J., Swash M., de Carvalho M. Awaji Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis: A Systematic Review. Arch. Neurol. 2012;69:1410&#x2013;1416. doi: 10.1001/archneurol.2012.254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.254</ArticleId><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen B., Pugdahl K., Fuglsang-Frederiksen A., Kollewe K., Paracka L., Dengler R., Camdessanch&#xe9; J.P., Nix W., Liguori R., Schofield I., et al. Diagnostic Criteria for Amyotrophic Lateral Sclerosis: A Multicentre Study of Inter-Rater Variation and Sensitivity. Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 2019;130:307&#x2013;314. doi: 10.1016/j.clinph.2018.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.11.021</ArticleId><ArticleId IdType="pubmed">30573424</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor B.J., Codd M.B., Corr B., Forde C., Frost E., Hardiman O.M. Clinical Features of Amyotrophic Lateral Sclerosis According to the El Escorial and Airlie House Diagnostic Criteria: A Population-Based Study. Arch. Neurol. 2000;57:1171. doi: 10.1001/archneur.57.8.1171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.8.1171</ArticleId><ArticleId IdType="pubmed">10927797</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Al-Chalabi A., Baker M.R., Cui L.-Y., de Carvalho M., Eisen A., Grosskreutz J., Hardiman O., Henderson R., Matamala J.M., et al. A Proposal for New Diagnostic Criteria for ALS. Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 2020;131:1975&#x2013;1978. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R. Diagnosing ALS: The Gold Coast Criteria and the Role of EMG. Pract. Neurol. 2022;22:176&#x2013;178. doi: 10.1136/practneurol-2021-003256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2021-003256</ArticleId><ArticleId IdType="pmc">PMC9120398</ArticleId><ArticleId IdType="pubmed">34992096</ArticleId></ArticleIdList></Reference><Reference><Citation>ALS CNTF Treatment Study Phase I&#x2013;II Group. Brooks B.R., Sanjak M. The Amyotrophic Lateral Sclerosis Functional Rating Scale: Assessment of Activities of Daily Living in Patients With Amyotrophic Lateral Sclerosis. Arch. Neurol. 1996;53:141&#x2013;147. doi: 10.1001/archneur.1996.00550020045014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1996.00550020045014</ArticleId><ArticleId IdType="pubmed">8639063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A Revised ALS Functional Rating Scale That Incorporates Assessments of Respiratory Function. J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche J.C., Rojas-Garcia R., Scott K.M., Scotton W., Ellis C.E., Burman R., Wijesekera L., Turner M.R., Leigh P.N., Shaw C.E., et al. A Proposed Staging System for Amyotrophic Lateral Sclerosis. Brain J. Neurol. 2012;135:847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Hammond E.R., Mora G., Bonito V., Filippini G. Development and Evaluation of a Clinical Staging System for Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2015;86:38&#x2013;44. doi: 10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C.N., Bedlack R., Quinn C., Russell J., Beckwith D., Kaminski K.H., Tyor W., Hertzberg V., James V., Polak M., et al. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) JAMA Neurol. 2020;77:480&#x2013;488. doi: 10.1001/jamaneurol.2019.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmaier S.L., Rhodes T., Cook S.F., Schlusser C., Chen C., Han S., Zach N., Murthy V., Dav&#xe9; S. Qualitative Measures That Assess Functional Disability and Quality of Life in ALS. Health Qual. Life Outcomes. 2022;20:12. doi: 10.1186/s12955-022-01919-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-022-01919-9</ArticleId><ArticleId IdType="pmc">PMC8781297</ArticleId><ArticleId IdType="pubmed">35062955</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Turner M.R., Wuu J. Defining Pre-Symptomatic Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:303&#x2013;309. doi: 10.1080/21678421.2019.1587634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Granit V., Andersen P.M., Grignon A.-L., McHutchison C., Cosentino S., Malaspina A., Wuu J. Mild Motor Impairment as Prodromal State in Amyotrophic Lateral Sclerosis: A New Diagnostic Entity. Brain. 2022;145:3500&#x2013;3508. doi: 10.1093/brain/awac185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac185</ArticleId><ArticleId IdType="pmc">PMC9586537</ArticleId><ArticleId IdType="pubmed">35594156</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J., Pender N.P., Hardiman O. Cognitive Impairment in Amyotrophic Lateral Sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Lynch C., Pender N., Hardiman O. The Syndrome of Cognitive Impairment in Amyotrophic Lateral Sclerosis: A Population-Based Study. J. Neurol. Neurosurg. Psychiatry. 2012;83:102&#x2013;108. doi: 10.1136/jnnp-2011-300188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300188</ArticleId><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuschi A., Iazzolino B., Calvo A., Moglia C., Lopiano L., Restagno G., Brunetti M., Ossola I., Lo Presti A., Cammarosano S., et al. Cognitive Correlates in Amyotrophic Lateral Sclerosis: A Population-Based Study in Italy. J. Neurol. Neurosurg. Psychiatry. 2015;86:168&#x2013;173. doi: 10.1136/jnnp-2013-307223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307223</ArticleId><ArticleId IdType="pubmed">24769471</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E., Raaphorst J., Klein Twennaar M., de Visser M., Schmand B.A., de Haan R.J. The Cognitive Profile of ALS: A Systematic Review and Meta-Analysis Update. J. Neurol. Neurosurg. Psychiatry. 2016;87:611&#x2013;619. doi: 10.1136/jnnp-2015-310734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310734</ArticleId><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Murphy J., Shoesmith C., Rosenfeld J., Leigh P.N., et al. Consensus Criteria for the Diagnosis of Frontotemporal Cognitive and Behavioural Syndromes in Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. 2009;10:131&#x2013;146. doi: 10.1080/17482960802654364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802654364</ArticleId><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J., Abrahams S., Goldstein L.H., Woolley S., Mclaughlin P., Snowden J., Mioshi E., Roberts-South A., Benatar M., Hortob&#xe1; Gyi T., et al. Amyotrophic Lateral Sclerosis-Frontotemporal Spectrum Disorder (ALS-FTSD): Revised Diagnostic Criteria. Amyotroph. Lateral Scler. Front. Degener. 2017;18:153&#x2013;174. doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., et al. Frontotemporal Lobar Degeneration: A Consensus on Clinical Diagnostic Criteria. Neurology. 1998;51:1546&#x2013;1554. doi: 10.1212/WNL.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., et al. Sensitivity of Revised Diagnostic Criteria for the Behavioural Variant of Frontotemporal Dementia. Brain J. Neurol. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselt I.K., Nijboer T.C.W., Van Es M.A. An Overview of Screening Instruments for Cognition and Behavior in Patients with ALS: Selecting the Appropriate Tool for Clinical Practice. Amyotroph. Lateral Scler. Front. Degener. 2020;21:324&#x2013;336. doi: 10.1080/21678421.2020.1732424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1732424</ArticleId><ArticleId IdType="pubmed">32157912</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S., Newton J., Niven E., Foley J., Bak T.H. Screening for Cognition and Behaviour Changes in ALS. Amyotroph. Lateral Scler. Front. Degener. 2014;15:9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S., Vielhaber S., Schreiber F., Cartwright M.S. Peripheral Nerve Imaging in Amyotrophic Lateral Sclerosis. Clin. Neurophysiol. 2020;131:2315&#x2013;2326. doi: 10.1016/j.clinph.2020.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.03.026</ArticleId><ArticleId IdType="pubmed">32340815</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewenbr&#xfc;ck K.F., Werner R., G&#xfc;nther R., Dittrich M., Klingenberger R., Reichmann H., Storch A., Hermann A. One Nerve Suffices: A Clinically Guided Nerve Ultrasound Protocol for the Differentiation of Multifocal Motor Neuropathy (MMN) and Amyotrophic Lateral Sclerosis (ALS) J. Neurol. 2021;268:1495&#x2013;1507. doi: 10.1007/s00415-020-10323-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10323-6</ArticleId><ArticleId IdType="pmc">PMC7990818</ArticleId><ArticleId IdType="pubmed">33355881</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzapfel K., Naumann M. Ultrasound Detection of Vagus Nerve Atrophy in Bulbar Amyotrophic Lateral Sclerosis. J. Neuroimaging. 2020;30:762&#x2013;765. doi: 10.1111/jon.12761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.12761</ArticleId><ArticleId IdType="pubmed">33167079</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulou M., Bakola E., Papapostolou A., Stefanou M.I., Moschovos C., Salakou S., Zis P., Zouvelou V., Kimiskidis V.K., Chroni E., et al. Autonomic Dysfunction in Amyotrophic Lateral Sclerosis: A Neurophysiological and Neurosonology Study. J. Neuroimaging Off. J. Am. Soc. Neuroimaging. 2022;32:710&#x2013;719. doi: 10.1111/jon.12993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.12993</ArticleId><ArticleId IdType="pubmed">35344230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein T., Sprenger A., Weiss K., Gro&#xdf;e Hokamp N., Maintz D., Schlamann M., Fink G.R., Lehmann H.C., Henning T.D. MRI DTI and PDFF as Biomarkers for Lower Motor Neuron Degeneration in ALS. Front. Neurosci. 2021;15:682126. doi: 10.3389/fnins.2021.682126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.682126</ArticleId><ArticleId IdType="pmc">PMC8428530</ArticleId><ArticleId IdType="pubmed">34512239</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon N.G., Lagopoulos J., Paling S., Pfluger C., Park S.B., Howells J., Gallagher T., Kliot M., Henderson R.D., Vucic S., et al. Peripheral Nerve Diffusion Tensor Imaging as a Measure of Disease Progression in ALS. J. Neurol. 2017;264:882&#x2013;890. doi: 10.1007/s00415-017-8443-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8443-x</ArticleId><ArticleId IdType="pubmed">28265751</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek S.-H., Park J., Kim Y.H., Seok H.Y., Oh K.-W., Kim H.-J., Kwon Y.-J., Sim Y., Tae W.-S., Kim S.H., et al. Usefulness of Diffusion Tensor Imaging Findings as Biomarkers for Amyotrophic Lateral Sclerosis. Sci. Rep. 2020;10:5199. doi: 10.1038/s41598-020-62049-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62049-0</ArticleId><ArticleId IdType="pmc">PMC7090054</ArticleId><ArticleId IdType="pubmed">32251314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J., M&#xfc;ller H.-P. Advanced Neuroimaging Approaches in Amyotrophic Lateral Sclerosis: Refining the Clinical Diagnosis. Expert Rev. Neurother. 2020;20:237&#x2013;249. doi: 10.1080/14737175.2020.1715798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1715798</ArticleId><ArticleId IdType="pubmed">31937156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocar T.D., Behler A., Ludolph A.C., M&#xfc;ller H.-P., Kassubek J. Multiparametric Microstructural MRI and Machine Learning Classification Yields High Diagnostic Accuracy in Amyotrophic Lateral Sclerosis: Proof of Concept. Front. Neurol. 2021;12:745475. doi: 10.3389/fneur.2021.745475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.745475</ArticleId><ArticleId IdType="pmc">PMC8637840</ArticleId><ArticleId IdType="pubmed">34867726</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan V., Pioro E.P. Comparing Brain Structural MRI and Metabolic FDG-PET Changes in Patients with ALS-FTD: &#x201c;the Chicken or the Egg?&#x201d; Question. J. Neurol. Neurosurg. Psychiatry. 2015;86:952&#x2013;958. doi: 10.1136/jnnp-2014-308239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308239</ArticleId><ArticleId IdType="pubmed">25520437</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K., Vanhee A., Verschueren J., De Coster L., Driesen A., Dupont P., Robberecht W., Van Damme P. Value of 18fluorodeoxyglucose-Positron-Emission Tomography in Amyotrophic Lateral Sclerosis: A Prospective Study. JAMA Neurol. 2014;71:553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C., Cistaro A., Campi C., Calvo A., Caponnetto C., Nobili F.M., Fania P., Beltrametti M.C., Moglia C., Novi G., et al. A PET/CT Approach to Spinal Cord Metabolism in Amyotrophic Lateral Sclerosis. Eur. J. Nucl. Med. Mol. Imaging. 2016;43:2061&#x2013;2071. doi: 10.1007/s00259-016-3440-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-016-3440-3</ArticleId><ArticleId IdType="pmc">PMC5007279</ArticleId><ArticleId IdType="pubmed">27421971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T., Hatakeyama T., Sato K., Fukui Y., Hishikawa N., Ohta Y., Nishiyama Y., Kawai N., Tamiya T., Abe K. Flow-Metabolism Uncoupling in the Cervical Spinal Cord of ALS Patients. Neurol. Sci. 2017;38:659&#x2013;665. doi: 10.1007/s10072-017-2823-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-2823-y</ArticleId><ArticleId IdType="pubmed">28120243</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M.J., Z&#xfc;rcher N.R., Loggia M.L., Cernasov P., Reynolds B., Pijanowski O., Chonde D.B., Izquierdo Garcia D., Mainero C., Catana C., et al. Integrated Magnetic Resonance Imaging and [11C]-PBR28 Positron Emission Tomographic Imaging in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2018;83:1186&#x2013;1197. doi: 10.1002/ana.25251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25251</ArticleId><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.-M., Masson G.L. Genetics of Amyotrophic Lateral Sclerosis: A Review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson S.B., Downie J.M., Tsetsou S., Feusier J.E., Figueroa K.P., Bromberg M.B., Jorde L.B., Pulst S.M. The Evolving Genetic Risk for Sporadic ALS. Neurology. 2017;89:226&#x2013;233. doi: 10.1212/WNL.0000000000004109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004109</ArticleId><ArticleId IdType="pmc">PMC5513819</ArticleId><ArticleId IdType="pubmed">28642336</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassano M., Calvo A., Moglia C., Sbaiz L., Brunetti M., Barberis M., Casale F., Manera U., Vasta R., Canosa A., et al. Systematic Evaluation of Genetic Mutations in ALS: A Population-Based Study. J. Neurol. Neurosurg. Psychiatry. 2022;93:1190&#x2013;1193. doi: 10.1136/jnnp-2022-328931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-328931</ArticleId><ArticleId IdType="pmc">PMC9606529</ArticleId><ArticleId IdType="pubmed">35896380</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A., McLaughlin R.L., Heverin M., Thorpe O., Abrahams S., Al-Chalabi A., Hardiman O. Genetic Testing in ALS: A Survey of Current Practices. Neurology. 2017;88:991&#x2013;999. doi: 10.1212/WNL.0000000000003686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003686</ArticleId><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khleifat A., Iacoangeli A., van Vugt J.J.F.A., Bowles H., Moisse M., Zwamborn R.A.J., van der Spek R.A.A., Shatunov A., Cooper-Knock J., Topp S., et al. Structural Variation Analysis of 6,500 Whole Genome Sequences in Amyotrophic Lateral Sclerosis. Npj Genomic Med. 2022;7:1&#x2013;8. doi: 10.1038/s41525-021-00267-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-021-00267-9</ArticleId><ArticleId IdType="pmc">PMC8799638</ArticleId><ArticleId IdType="pubmed">35091648</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud M., Gobet N., Cruz-D&#xe1;valos D.I., Mounier N., Dessimoz C., Sedlazeck F.J. Structural Variant Calling: The Long and the Short of It. Genome Biol. 2019;20:246. doi: 10.1186/s13059-019-1828-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1828-7</ArticleId><ArticleId IdType="pmc">PMC6868818</ArticleId><ArticleId IdType="pubmed">31747936</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold F.J., Merry D.E. Molecular Mechanisms and Therapeutics for SBMA/Kennedy&#x2019;s Disease. Neurother. J. Am. Soc. Exp. Neurother. 2019;16:928&#x2013;947. doi: 10.1007/s13311-019-00790-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00790-9</ArticleId><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansel A., Dorst J., Rosenbohm A., H&#xfc;bers A., Ludolph A.C. ALS Mimics. Neurol. Int. Open. 2018;02:E60&#x2013;E71. doi: 10.1055/s-0043-119960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0043-119960</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado D.A., Davidson B.L. Gene Therapy for ALS: A Review. Mol. Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans J.P., Skrzynia C., Burke W. The Complexities of Predictive Genetic Testing. BMJ. 2001;322:1052&#x2013;1056. doi: 10.1136/bmj.322.7293.1052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.322.7293.1052</ArticleId><ArticleId IdType="pmc">PMC1120190</ArticleId><ArticleId IdType="pubmed">11325775</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveri S., Ferrari F., Manfrinati A., Pravettoni G. A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases. Front. Genet. 2018;9:624. doi: 10.3389/fgene.2018.00624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00624</ArticleId><ArticleId IdType="pmc">PMC6295518</ArticleId><ArticleId IdType="pubmed">30619456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciorio R., Aiello R., Irollo A.M. Review: Preimplantation Genetic Diagnosis (PGD) as a Reproductive Option in Patients with Neurodegenerative Disorders. Reprod. Biol. 2021;21:100468. doi: 10.1016/j.repbio.2020.100468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.repbio.2020.100468</ArticleId><ArticleId IdType="pubmed">33321391</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Bucelli R.C., Andrews J.A., Otto M., Farahany N.A., Harrington E.A., Chen W., Mitchell A.A., et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study. Neurotherapeutics. 2022;19:1248&#x2013;1258. doi: 10.1007/s13311-022-01237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecoraro V., Mandrioli J., Carone C., Chi&#xf2; A., Traynor B.J., Trenti T. The NGS Technology for the Identification of Genes Associated with the ALS. A Systematic Review. Eur. J. Clin. Invest. 2020;50:e13228. doi: 10.1111/eci.13228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13228</ArticleId><ArticleId IdType="pmc">PMC9008463</ArticleId><ArticleId IdType="pubmed">32293029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P.R., Iacoangeli A., Opie-Martin S., van Vugt J.J.F.A., Al Khleifat A., Bredin A., Ossher L., Andersen P.M., Hardiman O., Mehta A.R., et al. The Impact of Age on Genetic Testing Decisions in Amyotrophic Lateral Sclerosis. Brain. 2022;145:4440&#x2013;4447. doi: 10.1093/brain/awac279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac279</ArticleId><ArticleId IdType="pmc">PMC9762932</ArticleId><ArticleId IdType="pubmed">36162820</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J., Quick A., Kolb S.J. Genetic Testing and Genetic Counseling for Amyotrophic Lateral Sclerosis: An Update for Clinicians. Genet. Med. 2017;19:267&#x2013;274. doi: 10.1038/gim.2016.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.107</ArticleId><ArticleId IdType="pubmed">27537704</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W., van der Spek R.A.A., Bakker M.K., van Vugt J.J.F.A., Hop P.J., Zwamborn R.A.J., de Klein N., Westra H.-J., Bakker O.B., Deelen P., et al. Common and Rare Variant Association Analyses in Amyotrophic Lateral Sclerosis Identify 15 Risk Loci with Distinct Genetic Architectures and Neuron-Specific Biology. Nat. Genet. 2021;53:1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K., Benatar M., Wuu J., Rampersaud E., Hennessy L., Van Deerlin V.M., Grossman M., Irwin D.J., Elman L., McCluskey L., et al. Machine Learning Suggests Polygenic Risk for Cognitive Dysfunction in Amyotrophic Lateral Sclerosis. EMBO Mol. Med. 2021;13:e12595. doi: 10.15252/emmm.202012595.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202012595</ArticleId><ArticleId IdType="pmc">PMC7799365</ArticleId><ArticleId IdType="pubmed">33270986</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehestani M., Liu H., Sreelatha A.A.K., Schulte C., Bansal V., Gasser T. Mitochondrial and Autophagy-Lysosomal Pathway Polygenic Risk Scores Predict Parkinson&#x2019;s Disease. Mol. Cell. Neurosci. 2022;121:103751. doi: 10.1016/j.mcn.2022.103751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2022.103751</ArticleId><ArticleId IdType="pubmed">35710056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M., Maia L.F., Preische O., Schelle J., Apel A., Kaeser S.A., Schweighauser M., Eninger T., Lambert M., Pilotto A., et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016;91:494&#x2013;496. doi: 10.1016/j.neuron.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.07.007</ArticleId><ArticleId IdType="pubmed">27477021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafson A.R., Barth&#xe9;lemy N.R., Bomont P., Carare R.O., Durham H.D., Julien J.-P., Kuhle J., Leppert D., Nixon R.A., Weller R.O., et al. Neurofilaments: Neurobiological Foundations for Biomarker Applications. Brain. 2020;143:1975&#x2013;1998. doi: 10.1093/brain/awaa098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa098</ArticleId><ArticleId IdType="pmc">PMC7363489</ArticleId><ArticleId IdType="pubmed">32408345</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Teunissen C.E., Otto M., Piehl F., Sormani M.P., Gattringer T., Barro C., Kappos L., Comabella M., Fazekas F., et al. Neurofilaments as Biomarkers in Neurological Disorders. Nat. Rev. Neurol. 2018;14:577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament Light: A Candidate Biomarker of Presymptomatic Amyotrophic Lateral Sclerosis and Phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K., De Schaepdryver M., Stubendorff B., Gille B., Muckova P., Wendler S., Prell T., Ringer T.M., Rhode H., Stevens O., et al. Neurofilament Markers for ALS Correlate with Extent of Upper and Lower Motor Neuron Disease. Neurology. 2017;88:2302&#x2013;2309. doi: 10.1212/WNL.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V., Mastrangelo A., Zenesini C., Masullo M., Quadalti C., Avoni P., Polischi B., Cherici A., Capellari S., Salvi F., et al. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Front. Aging Neurosci. 2021;13:753242. doi: 10.3389/fnagi.2021.753242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.753242</ArticleId><ArticleId IdType="pmc">PMC8569186</ArticleId><ArticleId IdType="pubmed">34744694</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Zhu Y., Hsiao-Nakamoto J., Tang X., Dugas J.C., Moscovitch-Lopatin M., Glass J.D., Brown R.H., Ladha S.S., Lacomis D., et al. Longitudinal Biomarkers in Amyotrophic Lateral Sclerosis. Ann. Clin. Transl. Neurol. 2020;7:1103&#x2013;1116. doi: 10.1002/acn3.51078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P., Jardel C., Salachas F., Lamari F., Andersen P.M., Bowser R., de Carvalho M., Costa J., van Damme P., Gray E., et al. Multicenter Validation of CSF Neurofilaments as Diagnostic Biomarkers for ALS. Amyotroph. Lateral Scler. Front. Degener. 2016;17:404&#x2013;413. doi: 10.3109/21678421.2016.1167913.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1167913</ArticleId><ArticleId IdType="pubmed">27415180</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Qin X., Chang X., Wang H., Guo J., Zhang W. Neurofilament Markers in Serum and Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. J. Cell. Mol. Med. 2022;26:583&#x2013;587. doi: 10.1111/jcmm.17100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17100</ArticleId><ArticleId IdType="pmc">PMC8743649</ArticleId><ArticleId IdType="pubmed">34866307</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Feneberg E., Weishaupt J., Brettschneider J., Tumani H., Andersen P.M., von Arnim C.A.F., B&#xf6;hm S., Kassubek J., Kubisch C., et al. Neurofilaments in the Diagnosis of Motoneuron Diseases: A Prospective Study on 455 Patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:12&#x2013;20. doi: 10.1136/jnnp-2015-311387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi A., Pujol-Calder&#xf3;n F., Tjust A.E., Wuolikainen A., H&#xf6;glund K., Forsberg K., Portelius E., Blennow K., Zetterberg H., Andersen P.M. Neurofilaments Can Differentiate ALS Subgroups and ALS from Common Diagnostic Mimics. Sci. Rep. 2021;11:22128. doi: 10.1038/s41598-021-01499-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01499-6</ArticleId><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="pubmed">34764380</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecca C., Dell&#x2019;Abate M.T., Pasculli G., Capozzo R., Barone R., Arima S., Pollice A., Brescia V., Tortelli R., Logroscino G. Role of Plasma Phosphorylated Neurofilament Heavy Chain (PNfH) in Amyotrophic Lateral Sclerosis. J. Cell. Mol. Med. 2022;26:3608&#x2013;3615. doi: 10.1111/jcmm.17232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17232</ArticleId><ArticleId IdType="pmc">PMC9258711</ArticleId><ArticleId IdType="pubmed">35715961</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Lee A., Murphy A., Chang J., Zipf A., Cudkowicz M., Atassi N. Diagnostic Timelines and Delays in Diagnosing Amyotrophic Lateral Sclerosis (ALS) Amyotroph. Lateral Scler. Front. Degener. 2014;15:453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Lombardi V., Jeromin A., Bowser R., Andersen P.M., Malaspina A. Neurofilaments in Pre-Symptomatic ALS and the Impact of Genotype. Amyotroph. Lateral Scler. Front. Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M., Masrori P., Van Damme P., Poesen K. Effect of Neurofilament Analysis on the Diagnostic Delay in Amyotrophic Lateral Sclerosis. CNS Neurosci. Ther. 2023;29:70&#x2013;77. doi: 10.1111/cns.13960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13960</ArticleId><ArticleId IdType="pmc">PMC9804063</ArticleId><ArticleId IdType="pubmed">36047371</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Steinacker P., Weishaupt J.H., Kassubek J., Oeckl P., Halbgebauer S., Tumani H., von Arnim C.A.F., Dorst J., Feneberg E., et al. Neurofilament Light Chain in Serum for the Diagnosis of Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Petzold A., Topping J., Allen K., Macdonald-Wallis C., Clarke J., Pearce N., Kuhle J., Giovannoni G., Fratta P., et al. Plasma Neurofilament Heavy Chain Levels and Disease Progression in Amyotrophic Lateral Sclerosis: Insights from a Longitudinal Study. J. Neurol. Neurosurg. Psychiatry. 2015;86:565&#x2013;573. doi: 10.1136/jnnp-2014-307672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselin F., De la Cruz E., Hirtz C., Tiers L., Alphandery S., Baudesson L., Taieb G., Camu W., Lehmann S. Repeated Neurofilament Light Chain Measurements Did Not Capture Riluzole Therapeutic Effect in Amyotrophic Lateral Sclerosis Patients. CNS Neurosci. Ther. 2022;28:1532&#x2013;1538. doi: 10.1111/cns.13894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13894</ArticleId><ArticleId IdType="pmc">PMC9437233</ArticleId><ArticleId IdType="pubmed">35751632</ArticleId></ArticleIdList></Reference><Reference><Citation>Walo-Delgado P.E., Sainz de la Maza S., Villarrubia N., Monreal E., Medina S., Espi&#xf1;o M., Fern&#xe1;ndez-Velasco J.I., Rodr&#xed;guez-Mart&#xed;n E., Rold&#xe1;n E., Lourido D., et al. Low Serum Neurofilament Light Chain Values Identify Optimal Responders to Dimethyl Fumarate in Multiple Sclerosis Treatment. Sci. Rep. 2021;11:9299. doi: 10.1038/s41598-021-88624-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88624-7</ArticleId><ArticleId IdType="pmc">PMC8085019</ArticleId><ArticleId IdType="pubmed">33927255</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras B.T., Crawford T.O., Finkel R.S., Mercuri E., De Vivo D.C., Oskoui M., Tizzano E.F., Ryan M.M., Muntoni F., Zhao G., et al. Neurofilament as a Potential Biomarker for Spinal Muscular Atrophy. Ann. Clin. Transl. Neurol. 2019;6:932&#x2013;944. doi: 10.1002/acn3.779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.779</ArticleId><ArticleId IdType="pmc">PMC6530526</ArticleId><ArticleId IdType="pubmed">31139691</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune Dysregulation in Amyotrophic Lateral Sclerosis: Mechanisms and Emerging Therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu M.E., Kozovska M., Appel S.H. Immune Reactivity in a Mouse Model of Familial ALS Correlates with Disease Progression. Neurology. 2001;57:1282&#x2013;1289. doi: 10.1212/WNL.57.7.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.7.1282</ArticleId><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Y&#xe1;&#xf1;ez A., Lall D., Wolf A.J., Muhammad A.K.M.G., Ho R., Carmona S., Vit J.P., Zarrow J., et al. C9orf72 Is Required for Proper Macrophage and Microglial Function in Mice. Science. 2016;351:1324&#x2013;1329. doi: 10.1126/science.aaf1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Engelhardt J.I., Sikl&#xf3;s L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., Appel S.H. Presence of Dendritic Cells, MCP-1, and Activated Microglia/Macrophages in Amyotrophic Lateral Sclerosis Spinal Cord Tissue. Ann. Neurol. 2004;55:221&#x2013;235. doi: 10.1002/ana.10805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean R.K., McKay F.C., Cretney E., Bye C.R., Perera N.D., Tomas D., Weston R.A., Scheller K.J., Djouma E., Menon P., et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018;75:681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous Regulatory T Lymphocytes Ameliorate Amyotrophic Lateral Sclerosis in Mice and Correlate with Disease Progression in Patients with Amyotrophic Lateral Sclerosis. Brain. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson M.P., Staff N.P., Bornschlegl S., Butler G.W., Maas M.L., Kazamel M., Zubair A., Gastineau D.A., Windebank A.J., Dietz A.B. Comprehensive Immune Profiling Reveals Substantial Immune System Alterations in a Subset of Patients with Amyotrophic Lateral Sclerosis. PLoS ONE. 2017;12:e0182002. doi: 10.1371/journal.pone.0182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., G&#xfc;nther R., Akg&#xfc;n K., Hermann A., Ziemssen T. Peripheral Proinflammatory Th1/Th17 Immune Cell Shift Is Linked to Disease Severity in Amyotrophic Lateral Sclerosis. Sci. Rep. 2020;10:5941. doi: 10.1038/s41598-020-62756-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Prado L.d.G.R., Rocha N.P., de Souza L.C., Bicalho I.C.S., Gomez R.S., Vidigal-Lopes M., Braz N.F.T., Vieira &#xc9;.L.M., Teixeira A.L. Longitudinal Assessment of Clinical and Inflammatory Markers in Patients with Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2018;394:69&#x2013;74. doi: 10.1016/j.jns.2018.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.033</ArticleId><ArticleId IdType="pubmed">30219498</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Zecca C., Piccininni M., Benmahamed S., Dell&#x2019;Abate M.T., Barulli M.R., Capozzo R., Battista P., Logroscino G. Plasma Inflammatory Cytokines Are Elevated in ALS. Front. Neurol. 2020;11:552295. doi: 10.3389/fneur.2020.552295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Cao C., Qin X.-Y., Yu Y., Yuan J., Zhao Y., Cheng Y. Increased Peripheral Blood Inflammatory Cytokine Levels in Amyotrophic Lateral Sclerosis: A Meta-Analysis Study. Sci. Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Hooten K.G., Sieglaff D.H., Zhang A., Kalyana-Sundaram S., Traini C.M., Halsey W.S., Hughes A.M., Sathe G.M., et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017;74:677&#x2013;685. doi: 10.1001/jamaneurol.2017.0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P., Carlesi C., Giungato P., Puxeddu I., Borroni B., Boss&#xf9; P., Migliorini P., Siciliano G., Boraschi D. Evaluating the Levels of Interleukin-1 Family Cytokines in Sporadic Amyotrophic Lateral Sclerosis. J. Neuroinflam. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Gerardi F., Tarlarini C., Filippi M., Riva N., Tremolizzo L., Diamanti S., Dellanoce C.C., Mosca L., et al. Urinary Neopterin, a New Marker of the Neuroinflammatory Status in Amyotrophic Lateral Sclerosis. J. Neurol. 2020;267:3609&#x2013;3616. doi: 10.1007/s00415-020-10047-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10047-7</ArticleId><ArticleId IdType="pubmed">32638112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Karnaros V., Benyamin B., Schultz D.W., Dubowsky M., Wuu J., Chataway T., Malaspina A., Benatar M., Rogers M.-L. Urinary Neopterin: A Novel Biomarker of Disease Progression in Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2022;29:990&#x2013;999. doi: 10.1111/ene.15237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15237</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B., Zhao W., Beers D.R., Henkel J.S., Appel S.H. Transformation from a Neuroprotective to a Neurotoxic Microglial Phenotype in a Mouse Model of ALS. Exp. Neurol. 2012;237:147&#x2013;152. doi: 10.1016/j.expneurol.2012.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan K.A., Weigel M.K., Adler D.I., Couthouis J., Liddelow S.A., Gitler A.D., Barres B.A. Knockout of Reactive Astrocyte Activating Factors Slows Disease Progression in an ALS Mouse Model. Nat. Commun. 2020;11:3753. doi: 10.1038/s41467-020-17514-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara J.H., Gautam M., Kocak N., Xie E.F., Mao Q., Bigio E.H., &#xd6;zdinler P.H. MCP1-CCR2 and Neuroinflammation in the ALS Motor Cortex with TDP-43 Pathology. J. Neuroinflam. 2019;16:196. doi: 10.1186/s12974-019-1589-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1589-y</ArticleId><ArticleId IdType="pmc">PMC6822373</ArticleId><ArticleId IdType="pubmed">31666087</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Jiang H., Qin X., Tian M., Zhang H. PET Imaging of Reactive Astrocytes in Neurological Disorders. Eur. J. Nucl. Med. Mol. Imaging. 2022;49:1275&#x2013;1287. doi: 10.1007/s00259-021-05640-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05640-5</ArticleId><ArticleId IdType="pmc">PMC8921128</ArticleId><ArticleId IdType="pubmed">34873637</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa M., Distefano G., Zorena K., Malaguarnera L. Chitinases and Immunity: Ancestral Molecules with New Functions. Immunobiology. 2016;221:399&#x2013;411. doi: 10.1016/j.imbio.2015.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2015.11.014</ArticleId><ArticleId IdType="pubmed">26686909</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Verde F., Fang L., Feneberg E., Oeckl P., Roeber S., Anderl-Straub S., Danek A., Diehl-Schmid J., Fassbender K., et al. Chitotriosidase (CHIT1) Is Increased in Microglia and Macrophages in Spinal Cord of Amyotrophic Lateral Sclerosis and Cerebrospinal Fluid Levels Correlate with Disease Severity and Progression. J. Neurol. Neurosurg. Psychiatry. 2018;89:239&#x2013;247. doi: 10.1136/jnnp-2017-317138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D., Wang G., Starkey A., Hamilton R.L., Wiley C.A. In vivo CHI3L1 (YKL-40) Expression in Astrocytes in Acute and Chronic Neurological Diseases. J. Neuroinflam. 2010;7:34. doi: 10.1186/1742-2094-7-34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-34</ArticleId><ArticleId IdType="pmc">PMC2892443</ArticleId><ArticleId IdType="pubmed">20540736</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinteac R., Montalban X., Comabella M. Chitinases and Chitinase-like Proteins as Biomarkers in Neurologic Disorders. Neurol. Neuroimmunol. Neuroinflam. 2021;8:e921. doi: 10.1212/NXI.0000000000000921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000921</ArticleId><ArticleId IdType="pmc">PMC7803328</ArticleId><ArticleId IdType="pubmed">33293459</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Bampton A., Raciborska D., Talbot K., Turner M.R. CSF Chitinase Proteins in Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1215&#x2013;1220. doi: 10.1136/jnnp-2019-320442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Van Den Bosch L., Tournoy J., Van Damme P., Poesen K. Inflammatory Markers in Cerebrospinal Fluid: Independent Prognostic Biomarkers in Amyotrophic Lateral Sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90:1338&#x2013;1346. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E., Thompson A.G., Wuu J., Pelt J., Talbot K., Benatar M., Turner M.R. CSF Chitinases before and after Symptom Onset in Amyotrophic Lateral Sclerosis. Ann. Clin. Transl. Neurol. 2020;7:1296&#x2013;1306. doi: 10.1002/acn3.51114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pmc">PMC7448184</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnello L., Colletti T., Lo Sasso B., Vidali M., Spataro R., Gambino C.M., Giglio R.V., Piccoli T., Bivona G., La Bella V., et al. Tau Protein as a Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2021;28:1868&#x2013;1875. doi: 10.1111/ene.14789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14789</ArticleId><ArticleId IdType="pubmed">33638255</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusina R., Ridzo&#x148; P., Kuli&#x161;t&#x2019;&#xe1;k P., Keller O., Barto&#x161; A., Buncov&#xe1; M., Fialov&#xe1; L., Koukol&#xed;k F., Mat&#x11b;j R. Relationship between ALS and the Degree of Cognitive Impairment, Markers of Neurodegeneration and Predictors for Poor Outcome. A Prospective Study: Risk Factors for Poor Outcome in ALS&#x2014;A Prospective Study. Eur. J. Neurol. 2010;17:23&#x2013;30. doi: 10.1111/j.1468-1331.2009.02717.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02717.x</ArticleId><ArticleId IdType="pubmed">19572947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bejan-Angoulvant T., Patin F., Andres C.R., Vourc&#x2019;h P., Corcia P., Blasco H. Plasma Creatinine and Amyotrophic Lateral Sclerosis Prognosis: A Systematic Review and Meta-Analysis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:199&#x2013;206. doi: 10.1080/21678421.2019.1572192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572192</ArticleId><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I., Alcolea D., Montal V., Dols-Icardo O., Mu&#xf1;oz L., de Luna N., Tur&#xf3;n-Sans J., Cort&#xe9;s-Vicente E., S&#xe1;nchez-Saudin&#xf3;s M.B., Subirana A., et al. CSF SAPP&#x3b2;, YKL-40, and NfL along the ALS-FTD Spectrum. Neurology. 2018;91:e1619&#x2013;e1628. doi: 10.1212/WNL.0000000000006383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006383</ArticleId><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V., Gregory J.M., Barria M.A., Green A., Pal S. TDP-43 as a Potential Biomarker for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. BMC Neurol. 2018;18:90. doi: 10.1186/s12883-018-1091-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1091-7</ArticleId><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y., Li S., Chen S., Sun X., Yang F., Wang H., Li M., Cui F., Huang X. TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. Front. Neurol. 2021;12:663637. doi: 10.3389/fneur.2021.663637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.663637</ArticleId><ArticleId IdType="pmc">PMC8236522</ArticleId><ArticleId IdType="pubmed">34194383</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I., Yacovzada N.S., Yanowski E., Coenen-Stass A., Grosskreutz J., Lu C.-H., Greensmith L., Malaspina A., Fratta P., Hornstein E. Circulating MiR-181 Is a Prognostic Biomarker for Amyotrophic Lateral Sclerosis. Nat. Neurosci. 2021;24:1534&#x2013;1541. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccanti M., Pozzilli V., Cambieri C., Libonati L., Onesti E., Frasca V., Fiorini I., Petrucci A., Garibaldi M., Palma E., et al. Creatine Kinase and Progression Rate in Amyotrophic Lateral Sclerosis. Cells. 2020;9:1174. doi: 10.3390/cells9051174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051174</ArticleId><ArticleId IdType="pmc">PMC7291088</ArticleId><ArticleId IdType="pubmed">32397320</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Gomez S., Radermacher B., Tacik P., Mirandola S.R., Heneka M.T., Weydt P. Teaching an Old Dog New Tricks: Serum Troponin T as a Biomarker in Amyotrophic Lateral Sclerosis. Brain Commun. 2021;3:fcab274. doi: 10.1093/braincomms/fcab274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab274</ArticleId><ArticleId IdType="pmc">PMC8728713</ArticleId><ArticleId IdType="pubmed">34993474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Z., Gao L., Guo J., Lu Y., Zang D. BFGF in the CSF and Serum of SALS Patients. Acta Neurol. Scand. 2015;132:171&#x2013;178. doi: 10.1111/ane.12381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12381</ArticleId><ArticleId IdType="pubmed">25631037</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg A., Skene N., Sanders F., Trusohamn M., Remnest&#xe5;l J., Szczepi&#x144;ska A., Aksoylu I.S., L&#xf6;nnerberg P., Ebarasi L., Wouters S., et al. Altered Perivascular Fibroblast Activity Precedes ALS Disease Onset. Nat. Med. 2021;27:640&#x2013;646. doi: 10.1038/s41591-021-01295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Chew J., Stankowski J.N., Hayes L.R., Zhang Y.-J., Prudencio M., Carlomagno Y., Daughrity L.M., Jansen-West K., Perkerson E.A., et al. Poly(GP) Proteins Are a Useful Pharmacodynamic Marker for C9ORF72-Associated Amyotrophic Lateral Sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan G., Raitcheva D., Bartlett D., Prudencio M., McKenna-Yasek D.M., Douthwright C., Oskarsson B.E., Ladha S., King O.D., Barmada S.J., et al. Poly(GR) and Poly(GA) in Cerebrospinal Fluid as Potential Biomarkers for C9ORF72-ALS/FTD. Nat. Commun. 2022;13:2799. doi: 10.1038/s41467-022-30387-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30387-4</ArticleId><ArticleId IdType="pmc">PMC9119980</ArticleId><ArticleId IdType="pubmed">35589711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X.R., Prudencio M., Koike Y., Vatsavayai S.C., Kim G., Harbinski F., Briner A., Rodriguez C.M., Guo C., Akiyama T., et al. TDP-43 Represses Cryptic Exon Inclusion in the FTD-ALS Gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Holloway R.G., Gramling R., Kelly A.G. Estimating and Communicating Prognosis in Advanced Neurologic Disease. Neurology. 2013;80:764&#x2013;772. doi: 10.1212/WNL.0b013e318282509c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318282509c</ArticleId><ArticleId IdType="pmc">PMC3589298</ArticleId><ArticleId IdType="pubmed">23420894</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H.-J., Debray T.P.A., Visser A.E., van Eijk R.P.A., Rooney J.P.K., Calvo A., Martin S., McDermott C.J., Thompson A.G., Pinto S., et al. Prognosis for Patients with Amyotrophic Lateral Sclerosis: Development and Validation of a Personalised Prediction Model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Levy G., Thompson J.L.P., Delbene M.L., Battista V., Gordon P.H., Rowland L.P., Levin B., Mitsumoto H. The ALSFRSr Predicts Survival Time in an ALS Clinic Population. Neurology. 2005;64:38&#x2013;43. doi: 10.1212/01.WNL.0000148648.38313.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148648.38313.64</ArticleId><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X.W., Simmons Z., Mitchell R.M., Kong L., Stephens H.E., Connor J.R. Biomarker-Based Predictive Models for Prognosis in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2013;70:1505&#x2013;1511. doi: 10.1001/jamaneurol.2013.4646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4646</ArticleId><ArticleId IdType="pubmed">24145899</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreger M., Steinbach R., Gaur N., Metzner K., Stubendorff B., Witte O.W., Grosskreutz J. Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. Front. Neurosci. 2021;15:651651. doi: 10.3389/fnins.2021.651651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.651651</ArticleId><ArticleId IdType="pmc">PMC8056017</ArticleId><ArticleId IdType="pubmed">33889072</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher S.A., Wong C., Pearson I.E., Pal S. Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-Analysis. JAMA Neurol. 2020;77:367&#x2013;376. doi: 10.1001/jamaneurol.2019.3924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3924</ArticleId><ArticleId IdType="pmc">PMC6865318</ArticleId><ArticleId IdType="pubmed">31738367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kj&#xe6;ldgaard A.-L., Pilely K., Olsen K.S., Jessen A.H., Lauritsen A.&#xd8;., Pedersen S.W., Svenstrup K., Karlsborg M., Thagesen H., Blaabjerg M., et al. Prediction of Survival in Amyotrophic Lateral Sclerosis: A Nationwide, Danish Cohort Study. BMC Neurol. 2021;21:164. doi: 10.1186/s12883-021-02187-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02187-8</ArticleId><ArticleId IdType="pmc">PMC8052712</ArticleId><ArticleId IdType="pubmed">33865343</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eenennaam R.M., Koppenol L.S., Kruithof W.J., Kruitwagen-van Reenen E.T., Pieters S., van Es M.A., van den Berg L.H., Visser-Meily J.M.A., Beelen A. Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study. Brain Sci. 2021;11:1597. doi: 10.3390/brainsci11121597.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11121597</ArticleId><ArticleId IdType="pmc">PMC8699408</ArticleId><ArticleId IdType="pubmed">34942899</ArticleId></ArticleIdList></Reference><Reference><Citation>Faghri F., Brunn F., Dadu A., Chi&#xf2; A., Calvo A., Moglia C., Canosa A., Manera U., Vasta R., Palumbo F., et al. Identifying and Predicting Amyotrophic Lateral Sclerosis Clinical Subgroups: A Population-Based Machine-Learning Study. Lancet Digit. Health. 2022;4:e359&#x2013;e369. doi: 10.1016/S2589-7500(21)00274-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(21)00274-0</ArticleId><ArticleId IdType="pmc">PMC9038712</ArticleId><ArticleId IdType="pubmed">35341712</ArticleId></ArticleIdList></Reference><Reference><Citation>Pancotti C., Birolo G., Rollo C., Sanavia T., Di Camillo B., Manera U., Chi&#xf2; A., Fariselli P. Deep Learning Methods to Predict Amyotrophic Lateral Sclerosis Disease Progression. Sci. Rep. 2022;12:13738. doi: 10.1038/s41598-022-17805-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17805-9</ArticleId><ArticleId IdType="pmc">PMC9374680</ArticleId><ArticleId IdType="pubmed">35962027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling Sporadic ALS in IPSC-Derived Motor Neurons Identifies a Potential Therapeutic Agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y., Ross J.P., Alipour P., Castonguay C.-&#xc9;., Li B., Catoire H., Rochefort D., Urushitani M., Takahashi R., Sonnen J.A., et al. Spinal Cord Extracts of Amyotrophic Lateral Sclerosis Spread TDP-43 Pathology in Cerebral Organoids. PLoS Genet. 2023;19:e1010606. doi: 10.1371/journal.pgen.1010606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1010606</ArticleId><ArticleId IdType="pmc">PMC9934440</ArticleId><ArticleId IdType="pubmed">36745687</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman M.J., Lim R.G., Wu J., Frank A., Ornelas L., Panther L., Galvez E., Perez D., Meepe I., Lei S., et al. Large-Scale Differentiation of IPSC-Derived Motor Neurons from ALS and Control Subjects. Neuron. 2023;111:1&#x2013;14. doi: 10.1016/j.neuron.2023.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2023.01.010</ArticleId><ArticleId IdType="pubmed">36764301</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Guan L., Deng M., Bolund L., Kristiansen K., Zhang J., Luo Y., Zhang Z. Integrative Genetic and Single Cell RNA Sequencing Analysis Provides New Clues to the Amyotrophic Lateral Sclerosis Neurodegeneration. Front. Neurosci. 2023;17 doi: 10.3389/fnins.2023.1116087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1116087</ArticleId><ArticleId IdType="pmc">PMC9983639</ArticleId><ArticleId IdType="pubmed">36875658</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Yada Y., Izumi Y., Morita M., Kawata A., Arisato T., Nagahashi A., Enami T., Tsukita K., Kawakami H., et al. Prediction Model of Amyotrophic Lateral Sclerosis by Deep Learning with Patient Induced Pluripotent Stem Cells. Ann. Neurol. 2021;89:1226&#x2013;1233. doi: 10.1002/ana.26047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26047</ArticleId><ArticleId IdType="pmc">PMC8247989</ArticleId><ArticleId IdType="pubmed">33565152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>